Elite Pharmaceuticals launches generic Ropinirole Extended-Release Tablets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
Tweet
Share
E-mailElite Pharmaceuticals, Inc. (OTCQB: ELTP) announced the commercial launch of its generic version of Requip XL (Ropinirole Extended-Release Tablets USP), available in 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg strengths.
Ropinirole is a non-ergoline dopamine agonist used to treat Parkinson's disease. The product is marketed and sold under the Elite Laboratories, Inc. label.
According to IQVIA data, the branded product and its equivalents recorded total U.S. sales of $10 million for the twelve months ending June 2026.
Elite Pharmaceuticals is based in Northvale, New Jersey, and operates a cGMP and DEA-registered manufacturing facility at that location.
You May Also Be Interested In
- International Paper assigns committee roles to two new board members
- Federal Reserve takes enforcement action against American Express over AML failures
- Guardant Health wins European approval for breast cancer companion diagnostic
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Maynard Um, Mark Zuckerberg, FDA, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
